The discovery and development of potent anti-hepatitis C virus (HCV) therapies has been a hotly contested field for global pharmaceutical companies over the last few decades. Some natural products, such as sangliferin A (SfA), have demonstrated potent anti-HCV activity through the inhibition of a clinically validated target, cyclophilin A (CypA).
Unfortunately, the chemical complexity of SfA and poor oral bioavailability have derailed all early drug development attempts.
This case study:
• Follows the success of Eurofins Discovery and their DiscoveryOne™ integrated drug discovery services team as they collaborate with a global pharma company.
• Demonstrates how Eurofins helped the company overcome the challenges faced in this area - with pleasing results!
